Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
Pharmaceutics · 28.09.2023 · 15 (10) · 2402
DOI: 10.3390/pharmaceutics15102402 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 28.09.2023. Verfasst von Dalia T Abdeldaim und 1 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Applied Biotechnology, University of Applied Science Biberach, 88400 Biberach, Germany. Die Arbeit wurde bisher 122-mal zitiert (Crossref) und nennt 174 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie, Deutsche Forschungsgemeinschaft, European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie.
Abstract (Originalsprache)
Monoclonal therapeutic antibodies have revolutionized the treatment of cancer and other diseases. Fc engineering aims to enhance the effector functions or half-life of therapeutic antibodies by modifying their Fc regions. Recent advances in the Fc engineering of modern therapeutic antibodies can be considered the next generation of antibody therapy. Various strategies are employed, including altering glycosylation patterns via glycoengineering and introducing mutations to the Fc region, thereby enhancing Fc receptor or complement interactions. Further, Fc engineering strategies enable the generation of bispecific IgG-based heterodimeric antibodies. As Fc engineering techniques continue to evolve, an expanding portfolio of Fc-engineered antibodies is advancing through clinical development, with several already approved for medical use. Despite the plethora of Fc-based mutations that have been analyzed in in vitro and in vivo models, we focus here in this review on the relevant Fc engineering strategies of approved therapeutic antibodies to finetune effector functions, to modify half-life and to stabilize asymmetric bispecific IgGs.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Applied Biotechnology, University of Applied Science Biberach, 88400 Biberach, Germany.
- Graduate School for Cellular and Biomedical Sciences, University of Bern, 3012 Bern, Switzerland.
ORCID-Profile: Katharina Schindowski
Förderung
- European Union's Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
- Deutsche Forschungsgemeinschaft
- European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie
Zitieren
APA
Abdeldaim, D. T., & Schindowski, K. (2023). Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics, 15(10), 2402. https://doi.org/10.3390/pharmaceutics15102402
Vancouver
Abdeldaim DT, Schindowski K. Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions. Pharmaceutics. 2023;15(10):2402. doi:10.3390/pharmaceutics15102402
BibTeX
@article{Abdeldaim2023,
author = {Abdeldaim, Dalia T and Schindowski, Katharina},
title = {Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {10},
pages = {2402},
doi = {10.3390/pharmaceutics15102402}
}
EUVIMED